Fig. 3From: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysisChanges in insulin dose during this study. Most participants have gradually reduced their insulin doses since the start of dulaglutide. Four out of 12 participants were able to stop using insulinBack to article page